Method of Preparing Oligonucleotide Compounds
AssigneeNogra Pharma Limited
InventorsAnthony Frank, Kevin Klopfer, Donald Joseph Gallagher, Jr., Laleh Jafarpour
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising oligonucleotides, specifically SMAD7 antisense oligonucleotides, and methods for preparing the same.
Claims55
A single batch composition of an oligonucleotide comprising at least 700 mmol of the oligonucleotide and at most 25 wt. % water;
- wherein the oligonucleotide has a nucleic acid sequence:
- SEQ ID NO:
- 3:
- (5′-GTX GCC CCT TCT CCC XGC AGC-3′),
- wherein X represents 5-methyl-2′-deoxycytidine.
A single batch composition of an oligonucleotide comprising at least 2 g/mmol of an at least 700 mmol synthesis scale of the oligonucleotide and at most 25 wt. % water;
- wherein the oligonucleotide has a nucleic acid sequence:
- SEQ ID NO:
- 3:
- (5′-GTX GCC CCT TCT CCC XGC AGC-3′),
- wherein X represents 5-methyl-2′-deoxycytidine.
A single batch composition of an oligonucleotide comprising at least 2 kg of the oligonucleotide and at most 25 wt. % water;
- wherein the oligonucleotide has a nucleic acid sequence:
- SEQ ID NO:
- 3:
- (5′-GTX GCC CCT TCT CCC XGC AGC-3′),
- wherein X represents 5-methyl-2′-deoxycytidine.
A single batch composition of an oligonucleotide comprising at least 50 mol % of the oligonucleotide output from at least one 700 mmol or greater oligonucleotide synthesis column and at most 25 wt. % water;
- wherein the oligonucleotide has a nucleic acid sequence:
- SEQ ID NO:
- 3:
- (5′-GTX GCC CCT TCT CCC XGC AGC-3′),
- wherein X represents 5-methyl-2′-deoxycytidine.
A substantially pure oligonucleotide composition of an oligonucleotide wherein the 5′-hydroxyl group of the 5′-terminal nucleoside is protected;
- wherein the oligonucleotide has a nucleic acid sequence:
- SEQ ID NO:
- 3:
- (5′-GTX GCC CCT TCT CCC XGC AGC-3′),
- wherein X represents 5-methyl-2′-deoxycytidine.
Dependencies are inferred from the claim text.